Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + ( p < 0.001). This trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A similar propensity-matched, more long term study reported larger differences between people who did and did not take ChEIs; in 1,572 patients with dementia, the average decrease in MMSE in those taking ChEIs was 5.4 points and 10.8 points in those not at the end of 13.6 years follow-up (p < 0.001).(495)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [495]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There was a strong association between ChEIs and lower all-cause mortality (HR 0.59, 0.53 -0.66).”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [495]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Diagnosis and Management of Dementia: Review
Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) · JAMA · doi:10.1001/jama.2019.4782 · Cited by 1,403
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015) · Trials · doi:10.1186/s13063-015-1023-4 · Cited by 878
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
McKeith, I. G. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s347 · Cited by 625
Research works printed but not linked: 2
- Kumar A, Sharma S. Donepezil. [Updated 2020 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513257/
- Nelson PT Kryscio RJ Abner EL Schmitt FA Jicha GA Mendiondo MS Cooper G Smith CB Markesbery WR Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with alzheimer's disease and AD + DLB J Alzheimers Dis. 2009 16 1 29 34 10.3233/JAD-2009-0926 19158418 PMC2682919 · DOI · Paper page
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Dementia Prevention and Treatment: A Narrative Review
Reuben, D. B., Kremen, S., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 202
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 301
Couteur, D. G. L., Hilmer, S. N., Glasgow, N., Naganathan, V., & Cumming, R. G. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg006.pub2 · Cited by 59
Zuliani, G., Zuin, M., Romagnoli, T., Polastri, M., Cervellati, C., & Brombo, G. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02675-6 · Cited by 52
“In 2022, Zuin et al. evaluated the effect of AChEI on cognitive decline and overall mortality in a sample of older patients with AD, VD or LBD enrolled between 2005 and 2020 by the National Alzheimer’s Coordinating Center Uni-form Data Set [31].”
BackgroundMethodSelf-citation
Metadata
- Authors
- Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G.
- Affiliations
- University of Ferrara (IT)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
- National Institutes of Health (US)
- Corresponding author
- Zuliani, Giovanni
- Venue
- Scientific Reports
- Published
- 2022-07-16
- Volume
- 12
- Issue
- 1
- Pages
- 12214-12214
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC9288483
- OpenAlex
- W4285588825
- Cited by
- 72
- References
- 38
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 19 · 2023: 13
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Funders
- NIA/NIH (U01 AG016976)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- acetylcholinesterase inhibitors, dementia, cognitive decline, all-cause mortality, late-onset Alzheimer's disease, vascular dementia, Lewy body disease, older adults, Mini-Mental State Examination, real-world effectiveness
- MeSH terms
- Aged, Alzheimer Disease, Cholinesterase Inhibitors, Cholinesterases, Humans, Lewy Body Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. https://app.cochat.ai/papers/10.1038/s41598-022-16476-w
- The paper
- Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G. (2022). Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Scientific Reports. https://doi.org/10.1038/s41598-022-16476-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.